A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

March 31, 2015

Study Completion Date

July 31, 2015

Conditions
Head and Neck CancerColon Cancer
Interventions
DRUG

Head and neck

"Eribulin mesylate is administered by IV infusion over 2-5 minutes on day 1 and 8 of a 21 day cycle 1.4mg/m2 and Cetuximab 400 mg/m2 cycle 1 week 1, then 250 mg/m2/weekly thereafter~Dose Level 1: 0.7 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 2: 1.0 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 3: 1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle"

DRUG

Colon- Closed as of May 2014

"Eribulin Mesylate:~1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle"

Trial Locations (4)

10467

Montefiore, The Bronx

02860

Memorial Hospital, Pawtucket

02903

Rhode Island Hospital, Providence

02904

The Miriam Hospital, Providence

All Listed Sponsors
collaborator

Fatima Memorial Hospital

OTHER

collaborator

Montefiore Medical Center

OTHER

collaborator

Rhode Island Hospital

OTHER

collaborator

The Miriam Hospital

OTHER

lead

howard safran

OTHER

NCT01744340 - A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer | Biotech Hunter | Biotech Hunter